AstraZeneca to build $200m center in China

    Updated: 2011-10-12 09:56

    By Ma Zhenhuan (China Daily)

      Comments() Print Mail Large Medium  Small 分享按鈕 0

    AstraZeneca to build $200m center in China

    AstraZeneca PLC workers load blister strips onto a packing line at a factory in Macclesfield, United Kingdom. The UK-based medical company will create 600 jobs by building a new factory in Taizhou, Jiangsu province. [Photo / Bloomberg]

    SHANGHAI - AstraZeneca PLC, one of the world's leading pharmaceutical companies, said it would invest $200 million to launch a new manufacturing facility in China to meet growing demand, including in rural areas.

    Construction work on the project, in the China Medical City in Taizhou of East China's Jiangsu province, is scheduled for completion by the end of 2013, creating approximately 600 jobs.

    This will be London-based AstraZeneca's largest single investment in a manufacturing facility globally. The new plant will produce intravenous and oral solid products, the company said.

    "The new facility will significantly enhance our capacity and allow us to meet the growing healthcare demand of the Chinese population, and help us expand into the 900 million (rural) people outside of the big cities and hospitals," Mark Mallon, president of AstraZeneca China, told China Daily in an exclusive interview on Monday.

    "It will also allow us to free up some capacity at our existing manufacturing facility in Wuxi, Jiangsu, to bring on more new innovative products that will be launched over the next few years," he added.

    The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010, according to market research agency IMS Health Inc, and it is expected to reach $102 billion by 2015.

    Mallon said that he believes the Chinese government's focus on healthcare reform and investment in improving healthcare infrastructure and expanding insurance coverage will continue to drive the company's business growth and increase access to quality medicines over the longer term.

    AstraZeneca will launch two new products, Faslodex, a treatment for breast cancer, and Onglyza, a new treatment for Type-2 Diabetes, in China this year.

    Mallon also mentioned that the company is planning to launch Brilinta, an oral antiplatelet treatment for acute coronary syndrome, next year in China.

    With an enhanced manufacturing capacity and the launch of more innovative new medicines, the company is planning to produce more affordable medicines for Chinese patients. It will adopt a multi-channel approach to sell its products to markets beyond big cities and hospitals.

    Aside from the medical sales representatives who deal with individual physicians in big cities, the company has developed a team of about 100 customer service representatives who organize educational programs for small clinics and community health centers in China's rural areas.

    It will also set up an inbound and outbound call center to reach out to healthcare professionals through phone calls, helping them learn more about AstraZeneca products, he said.

    The company, which entered China in 1993, has invested about $500 million in the country, including an innovation center in Zhangjiang, Shanghai.

    久久亚洲精品无码VA大香大香| 亚洲AV无码专区国产乱码4SE| 亚洲人成无码网站| 亚洲av无码一区二区三区人妖| 精品亚洲AV无码一区二区三区| 久久久久久亚洲精品无码| 亚洲熟妇无码乱子AV电影| 中文字幕亚洲色图| 97久久精品无码一区二区| 中文字幕一区在线观看视频| 人妻少妇精品无码专区动漫| 久久精品无码一区二区无码| 中文字幕日韩第十页在线观看| 中文字幕乱偷无码AV先锋| 久久久久久亚洲精品无码| 无码av免费一区二区三区| 日韩人妻无码一区二区三区久久99| 爆操夜夜操天天操中文| 亚洲AV中文无码乱人伦| 国产精品多人p群无码| 丰满日韩放荡少妇无码视频 | 国产av永久无码天堂影院| 中文精品99久久国产| 91天日语中文字幕在线观看| 久久久噜噜噜久久中文福利| 国产精品中文久久久久久久| 亚洲中文字幕无码爆乳av中文| 国产福利电影一区二区三区久久老子无码午夜伦不 | 无码成人一区二区| 亚洲色偷拍另类无码专区| 狠狠精品久久久无码中文字幕| 开心久久婷婷综合中文字幕| 最近免费中文字幕大全免费版视频| 波多野结衣中文在线播放| 无码人妻黑人中文字幕| 久久精品天天中文字幕人妻| а中文在线天堂| 无码夫の前で人妻を侵犯| 无码精品国产dvd在线观看9久 | 免费a级毛片无码a∨免费软件 | 色综合久久久久无码专区|